Japanese encephalitis vaccine (Ixiaro)
Ability to drive, Japanese encephalitis vaccine [2] ---> SmPC of [2] of EMA
IXIARO has no or negligible influence on the ability to drive and use machines.
Breast-feeding [1], Japanese encephalitis vaccine ---> SmPC of [1] of EMA
However, in the absence of data and as a precautionary measure the use of IXIARO during lactation should be avoided.
Fertility, Japanese encephalitis vaccine [2] ---> SmPC of [2] of EMA
A study in rats did not indicate vaccine-related effects on female reproduction, foetal weight, survival and development of the off-spring.
Immunosuppressives, Japanese encephalitis vaccine [2] ---> SmPC of [2] of EMA
In patients receiving immunosuppressive therapy or patients with immunodeficiency an adequate immune response may not be obtained.
Japanese encephalitis vaccine [1], pregnancy ---> SmPC of [1] of EMA
As a precautionary measure, the use of IXIARO during pregnancy should be avoided.
Japanese encephalitis vaccine [1], vaccinations ---> SmPC of [1] of EMA
There was no interference with the immune response to Japanese encephalitis virus (JEV) or to hepatitis A or rabies virus vaccines
CONTRAINDICATIONS of Japanese encephalitis vaccine (Ixiaro)
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to the residues protamine sulphate, formaldehyde, bovine serum albumin, host cell DNA, sodium metabisulphite, host cell protein.
- Individuals who show hypersensitivity reactions after receiving the first dose of the vaccine should not be given the second dose.
- Administration must be postponed in persons with acute severe febrile conditions.
https://www.ema.europa.eu/en/documents/product-information/ixiaro-epar-product-information_en.pdf 12/04/2021